Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Aims To Get Nutritionals Back On Track In Wake Of Similac Recall

This article was originally published in The Tan Sheet

Executive Summary

Abbott says its nutrition business is on track for a return to full-scale production and growth after absorbing an expected $100 million hit to third-quarter sales from its September Similac recall

You may also be interested in...

In Brief

Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.

Sales & Earnings In Brief

Mead Johnson forecasts slower growth in China; Abbott reclaims nutritional market share; Colgate expects product launches to drive 2012 growth

Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions

Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts